Akouos Overview
- Year Founded
-
2016
- Status
-
Acquired/Merged
- Employees
-
103
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$449M
Akouos General Information
Description
Akouos Inc is a genetic medicine company focused on developing gene therapies that restore, improve, and preserve hearing. The company is involved in developing potential genetic medicines for a variety of inner ear disorders, thereby enabling its clients to be provided with advancing precision genetic therapies with the potential to restore, improve and preserve hearing.
Contact Information
Website
www.akouos.com(Operating Subsidiary)
Corporate Office
- 645 Summer Street
- Suite 200
- Boston, MA 02210
- United States
Corporate Office
- 645 Summer Street
- Suite 200
- Boston, MA 02210
- United States
Akouos Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 01-Dec-2022 | $449M | Completed | Generating Revenue | ||
| 6. IPO | 26-Jun-2020 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series B) | 03-Mar-2020 | Completed | Startup | |||
| 4. Early Stage VC (Series A) | 07-Aug-2018 | Completed | Startup | |||
| 3. Seed Round | 13-Nov-2017 | Completed | Startup | |||
| 2. Accelerator/Incubator | 05-Oct-2017 | Completed | Startup | |||
| 1. Accelerator/Incubator | 13-Oct-2016 | Completed | Startup |
Akouos Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Seed I | 2,058,855 | $0.000100 | $0.02 | $0.24 | $0.24 | 1x | $0.24 | 0.41% |
| Seed | 25,622,520 | $0.000100 | $0.02 | $0.28 | $0.28 | 1x | $0.28 | 5.06% |
Akouos Comparisons
Industry
Financing
Details
Akouos Competitors (14)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Decibel Therapeutics | Formerly VC-backed | Boston, MA | ||||
| Frequency Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Acousia Therapeutics | Venture Capital-Backed | Tubingen, Germany | ||||
| Autifony Therapeutics | Formerly VC-backed | Stevenage, United Kingdom |
Akouos Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Akouos Patents
Akouos Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240167056-A1 | Cell specific gene therapy delivery compositions and methods for treating hearing loss | Pending | 09-May-2022 | ||
| US-20240252685-A1 | Cell specific gene therapy delivery compositions and methods for treating hearing loss | Pending | 09-May-2022 | ||
| AU-2023215253-A1 | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms | Pending | 02-Feb-2022 | ||
| AU-2022358579-A1 | Gene therapy delivery compositions and methods for treating hearing loss | Pending | 30-Sep-2021 | ||
| AU-2022356427-A1 | Compositions and methods for treating kcnq4-associated hearing loss | Pending | 30-Sep-2021 | C07K14/705 |
Akouos Executive Team (17)
| Name | Title | Board Seat |
|---|---|---|
| Jennifer Wellman | Chief Operating Officer | |
| Karoline Shair | Chief Legal Officer & Corporate Secretary | |
| Aaron Tward | Chief Scientific Officer | |
| Luk Vandenberghe Ph.D | Co-Founder & Member of Scientific Advisory Board | |
| Richard Smith MD | Co-Founder |
Akouos Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Edward Mathers | New Enterprise Associates | Board Member | |
| Kush Parmar Ph.D | 5AM Ventures | Board Member | |
| Vicki Sato Ph.D | Self | Board Member |
Akouos Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Akouos Former Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 5AM Ventures | Venture Capital | Minority | ||
| Citadel Enterprise Americas | Hedge Fund | Minority | ||
| Cormorant Asset Management | Hedge Fund | Minority | ||
| Cowen Healthcare Investments | Venture Capital | Minority | ||
| EcoR1 Capital | Venture Capital | Minority |
Akouos FAQs
-
When was Akouos founded?
Akouos was founded in 2016.
-
Who is the founder of Akouos?
Emmanuel Simons Ph.D, Luk Vandenberghe Ph.D, Richard Smith MD, William Sewell Ph.D, and Michael McKenna Ph.D are the founders of Akouos.
-
Where is Akouos headquartered?
Akouos is headquartered in Boston, MA.
-
What is the size of Akouos?
Akouos has 103 total employees.
-
What industry is Akouos in?
Akouos’s primary industry is Drug Discovery.
-
Is Akouos a private or public company?
Akouos is a Private company.
-
What is the current valuation of Akouos?
The current valuation of Akouos is .
-
What is Akouos’s current revenue?
The current revenue for Akouos is .
-
How much funding has Akouos raised over time?
Akouos has raised $375M.
-
Who are Akouos’s investors?
5AM Ventures, Citadel Enterprise Americas, Cormorant Asset Management, Cowen Healthcare Investments, and EcoR1 Capital are 5 of 20 investors who have invested in Akouos.
-
Who are Akouos’s competitors?
NexImmune, Decibel Therapeutics, Frequency Therapeutics, Acousia Therapeutics, and Autifony Therapeutics are some of the 14 competitors of Akouos.
-
When was Akouos acquired?
Akouos was acquired on 01-Dec-2022.
-
Who acquired Akouos?
Akouos was acquired by Eli Lilly and Company.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
